Karyopharm Therapeutics Inc. (KPTIQ)
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Karyopharm Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.0290 | 0.0417 | 0.0286 | 0.0398 | 2,313,371 |
| Nov 16, 2026 | 0.0220 | 0.0290 | 0.0220 | 0.0286 | 1,373,924 |
| Nov 13, 2026 | 0.0275 | 0.0290 | 0.0210 | 0.0254 | 1,575,002 |
| Nov 12, 2026 | 0.0102 | 0.0275 | 0.0102 | 0.0255 | 2,847,972 |
| Nov 11, 2026 | 0.0080 | 0.0200 | 0.0080 | 0.0175 | 8,359,730 |
| Name | Shares | % | Source |
|---|---|---|---|
RA Capital Management, L.P. · joint filing· may incl. warrants· filed Nov 2026 | 2.5M | 11.1% | 13G |
Adage Capital Management, L.P. · also on 13F· joint filing· may incl. warrants· filed Nov 2026 | 2.0M | 8.9% | 13G |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.0M | 8.8% | 13F |
Affinity Asset Advisors, LLC · joint filing· filed Nov 2026 | 0+1.6M via warrants | 6.9% | 13G |
T. Rowe Price Investment Management, Inc. · may incl. warrants· filed Jun 2026 | 1.5M | 6.8% | 13G |
BlackRock, Inc. | 1.5M | 6.7% | 13F |
ACORN CAPITAL ADVISORS, LLC | 1.2M | 5.4% | 13F |
Anders Hove · joint filing· may incl. warrants· reaffirmed 13F Nov 2026 | 1.0M | 4.5% | 13G |
Catalio Capital Management, LP | 976.2K | 4.3% | 13F |
UBS Group AG | 963.9K | 4.2% | 13F |
Insiders
- Mason MichaelEVP, CFO & Treasurer
- Paulson Richard A.President and CEO, Director
- Cheng Sohanya RoshanEVP & Chief Commercial Officer
- Poulton StuartEVP, Chief Development Officer
- Mano MichaelEVP, CLO&Secretary
- Macomber LoriEVP, CFO & Treasurer
- Rangwala ReshmaEVP & Chief Medical Officer
- Abate KristinChief Accounting Officer
- BOHLIN GAREN GDirector
- Greene Barry EDirector
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors.
In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
based on 22.68M shares outstanding
30d Avg
3.28M
60d Avg
3.28M
90d Avg
3.28M
Karyopharm Therapeutics Inc. (OTC: KPTIQ) traded at $0.0398 on Nov 17, 2026, up 39.16% from the previous close of $0.0286. The company is in the Healthcare sector (Medical - Pharmaceuticals).